Kaken Pharmaceutial
4521.TPharmaceutical
Filed as KAKEN PHARMACEUTICAL CO., LTD. (2022-06–2026-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥76.9bn | ¥94.0bn | ¥72.0bn | ¥73.0bn | ¥76.0bn | ¥75.0bn |
| Operating income | −¥899m | ¥21.0bn | ¥9.5bn | ¥8.0bn | ¥17.1bn | ¥17.8bn |
| Ordinary income | −¥206m | ¥21.3bn | ¥10.0bn | ¥8.7bn | ¥17.5bn | ¥18.2bn |
| Net income (owners) | ¥2.1bn | ¥13.9bn | ¥8.0bn | ¥5.4bn | ¥9.5bn | ¥13.4bn |
| Total assets | ¥178.2bn | ¥193.4bnr | ¥171.6bn | ¥166.3bn | ¥165.2bn | ¥163.3bn |
| Net assets / equity | ¥147.6bn | ¥152.6bnr | ¥143.8bn | ¥136.8bn | ¥138.3bn | ¥136.3bn |
| Operating cash flow | −¥11.1bn | ¥29.8bn | ¥2.6bn | ¥9.3bn | ¥13.3bn | ¥14.4bn |
| EPS (basic) | ¥56.57 | ¥365.42 | ¥212.67 | ¥144.8 | ¥251.43 | ¥347.37 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 203 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 203 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 203 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Medicine | ¥74.3bn | −¥2.3bn |
| Real Estate | ¥2.5bn | ¥1.4bn |
| Adjustments & eliminations | — | — |
| Total | ¥76.9bn | −¥899m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.